Institute of Health Science, Health Science Business Division, Kirin Holdings Company, Limited, Fujisawa, Kanagawa 251-8555, Japan.
Soiken Inc., Chiyoda, Tokyo 101-0052, Japan.
Nutrients. 2024 Oct 1;16(19):3333. doi: 10.3390/nu16193333.
BACKGROUND/OBJECTIVES: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients.
Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4.
The IBS-severity scoring system significantly decreased in all patients (-38.0 [95% confidence interval (CI): -53.6, -22.4]; < 0.001), in patients with IBS-D (-44.5 [95% CI: -70.6, -18.5]; = 0.004) and IBS-C (-51.2 [95% CI: -79.4, -22.9]; = 0.002), but not in those with IBS-M (-20.0 [95% CI: -48.0, 8.1]; = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention.
In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.
背景/目的:益生菌和益生元已被报道可改善肠易激综合征(IBS)的症状。然而,益生菌和益生元的效果可能因 IBS 亚型而异。本研究旨在调查基于肠道微生物群和 IBS 亚型的个性化益生元和益生菌补充剂对患者的影响。
招募了腹泻型 IBS(IBS-D)、便秘型 IBS(IBS-C)和混合型 IBS(IBS-M)患者(每组 40 例;总计 120 例)。根据 IBS 亚型和肠道微生物群确定个性化的益生元和益生菌补充剂。患者接受补充剂治疗 4 周。主要结局是从基线到第 4 周 IBS 严重程度评分系统的变化。
所有患者的 IBS 严重程度评分系统均显著降低(-38.0 [95%置信区间(CI):-53.6,-22.4];<0.001),IBS-D 患者(-44.5 [95% CI:-70.6,-18.5];=0.004)和 IBS-C 患者(-51.2 [95% CI:-79.4,-22.9];=0.002),但 IBS-M 患者则没有(-20.0 [95% CI:-48.0,8.1];=0.47)。在这项研究中,没有观察到与干预有因果关系的严重不良事件。
总之,根据个体肠道微生物群和 IBS 亚型选择的个性化益生元和益生菌补充剂可能缓解 IBS 症状的严重程度,特别是在 IBS-C 和 IBS-D 患者中。